Negative Results End Development Program of Treating JIA with GLM

Summary

This article presents the 48-week results of the Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis and Multiple Joint Involvement Who Have Poor Response to Methotrexate [GO KIDS; NCT01230827].

  • Rheumatology Clinical Trials Arthritis
  • Rheumatological Autoimmune Disorders
  • Rheumatology Clinical Trials
  • Rheumatology
  • Arthritis
  • Rheumatological Autoimmune Disorders
View Full Text